Evidence map›Paper›PMID 42383574›Full record

ArticleThoracic cancer2026

BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma.

Reina Imase, Rie Sakakibara, Susumu Kirimura, Hironori Ishibashi, Kenichi Okubo, Yasunari Miyazaki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Reina ImaseDepartment of Respiratory Medicine, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0009-0006-7713-288X
Rie SakakibaraDepartment of Respiratory Medicine, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0009-0003-6636-224X
Susumu KirimuraDepartment of Pathology, Institute of Science Tokyo, Tokyo, Japan.
Hironori IshibashiDepartment of Thoracic Surgery, Institute of Science Tokyo, Tokyo, Japan.
Kenichi OkuboDepartment of Thoracic Surgery, Institute of Science Tokyo, Tokyo, Japan.
Yasunari MiyazakiDepartment of Respiratory Medicine, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-9073-9815

Funding

Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, including JSPS KAKENHI JP25K19460
6 · The paper itself

Abstract

introductionReliable predictive biomarkers for immune checkpoint inhibitors (ICIs) in pleural mesothelioma (PM) are lacking. Loss of BRCA1-associated protein 1 (BAP1) is a frequent molecular alteration in PM and may influence the tumor immune microenvironment. We evaluated whether BAP1 loss is associated with clinical outcomes following immunotherapy.

methodsWe retrospectively analyzed 14 patients with PM who were treated with ICIs between April 2014 and May 2024. BAP1 status was assessed by immunohistochemical staining of resected tumor specimens. Patients were categorized into BAP1-loss and BAP1-positive groups. Progression-free survival (PFS), overall survival (OS), response rate (RR), and disease control rate (DCR) were compared.

resultsBAP1 loss was observed in nine patients (64%). Median PFS was significantly longer in the BAP1-loss group compared with the BAP1-positive group (5.3 vs. 2.1 months; log-rank p = 0.03). Median OS was also prolonged in the BAP1-loss group (8.6 vs. 2.1 months; log-rank p = 0.03). RR and DCR were numerically higher among patients with BAP1 loss.

conclusionBAP1 loss was associated with improved clinical outcomes following immunotherapy in PM. These findings support that a molecular profile that includes BAP1 deletion may serve as a biomarker for predicting response to immunotherapy in PM.

Indexed as

Biomarkers, TumorImmunotherapyMesotheliomaMesothelioma, MalignantPleural NeoplasmsTumor Suppressor ProteinsUbiquitin ThiolesteraseAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesBAP1 protein, humanBiomarkers, TumorTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1immune checkpoint inhibitorimmunohistochemistryimmunotherapypleural mesothelioma

Identifiers

PMID42383574
PMCPMC13321164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.